Adaptive Biotechnologies (ADPT) Financials

$9.15 +0.01 (+0.11%)

Closing price 04:00 PM Eastern

Extended Trading

$9.15 0.00 (0.00%)

As of 04:47 PM Eastern

Annual Income Statements for Adaptive Biotechnologies

This table shows Adaptive Biotechnologies' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017
Net Income / (Loss) Attributable to Common Shareholders	-159	-225	-200	-207	-146	-70	-46	-43
Consolidated Net Income / (Loss)	-160	-225	-200	-207	-146	-69	-46	-43
Net Income / (Loss) Continuing Operations	-160	-225	-200	-207	-146	-69	-46	-43
Total Pre-Tax Income	-160	-225	-200	-207	-146	-69	-46	-43
Total Operating Income	-163	-227	-200	-209	-153	-78	-50	-44
Total Gross Profit	107	95	127	105	76	63	36	0.01
Total Revenue	179	170	185	154	98	85	56	16
Operating Revenue	179	170	185	154	98	85	56	16
Total Cost of Revenue	72	76	58	49	23	22	20	16
Operating Cost of Revenue	72	76	58	49	23	22	20	16
Total Operating Expenses	269	322	328	314	229	141	86	44
Selling, General & Admin Expense	73	84	89	75	50	30	20	16
Marketing Expense	85	89	96	95	61	38	24	17
Research & Development Expense	103	122	142	142	116	71	39	32
Amortization Expense	1.70	1.70	1.70	1.70	1.70	1.70	1.70	1.69
Impairment Charge	7.21	25	0.00	0.00	-	-	-	-
Total Other Income / (Expense), net	2.95	1.73	-0.18	1.67	6.59	9.79	3.31	1.64
Interest Expense	12	14	4.24	0.00	0.00	-	-	-
Interest & Investment Income	15	16	4.06	1.67	6.59	9.79	3.31	1.64
Net Income / (Loss) Attributable to Noncontrolling Interest	-0.10	-0.05	-0.18	-0.02	0.00	0.00	-	-
Basic Earnings per Share	($1.08)	($1.56)	($1.40)	($1.48)	($1.11)	($1.01)	($3.67)	($3.50)
Weighted Average Basic Shares Outstanding	147.10M	144.38M	142.52M	140.35M	131.22M	69.17M	12.63M	12.20M
Diluted Earnings per Share	($1.08)	($1.56)	($1.40)	($1.48)	($1.11)	($1.01)	($3.67)	($3.50)
Weighted Average Diluted Shares Outstanding	147.10M	144.38M	142.52M	140.35M	131.22M	69.17M	12.63M	12.20M
Weighted Average Basic & Diluted Shares Outstanding	148.58M	145.09M	143.23M	140.35M	131.22M	69.17M	12.63M	12.20M

This table shows Adaptive Biotechnologies' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-30	-34	-32	-46	-48	-69	-50	-48	-58	-40	-45
Consolidated Net Income / (Loss)	-30	-34	-32	-46	-48	-69	-50	-48	-58	-40	-45
Net Income / (Loss) Continuing Operations	-30	-34	-32	-46	-48	-69	-50	-48	-58	-40	-45
Total Pre-Tax Income	-30	-34	-32	-46	-48	-69	-50	-48	-58	-40	-45
Total Operating Income	-30	-34	-33	-47	-49	-71	-51	-48	-57	-39	-45
Total Gross Profit	35	29	30	24	24	26	19	31	19	39	33
Total Revenue	52	47	46	43	42	46	38	49	38	55	48
Operating Revenue	52	47	46	43	42	46	38	49	38	55	48
Total Cost of Revenue	17	18	17	19	18	20	19	18	19	17	15
Operating Cost of Revenue	17	18	17	19	18	20	19	18	19	17	15
Total Operating Expenses	65	63	62	71	73	97	70	79	76	78	78
Selling, General & Admin Expense	17	18	17	18	20	21	20	22	21	22	21
Marketing Expense	23	22	21	20	22	22	20	24	22	24	22
Research & Development Expense	24	23	24	25	30	29	29	32	33	31	36
Amortization Expense	0.42	0.43	0.43	0.42	0.42	0.43	0.43	0.42	0.42	0.43	0.43
Impairment Charge	0.00	-	0.00	7.21	0.00	25	0.00	0.00	0.00	-	-
Total Other Income / (Expense), net	-0.23	0.12	0.54	1.07	1.23	1.60	0.63	0.01	-0.51	-0.98	0.11
Interest Expense	2.91	2.95	2.94	2.70	2.99	3.01	3.65	3.61	3.53	3.59	0.65
Interest & Investment Income	2.68	3.07	3.47	3.77	4.22	4.61	4.28	3.61	3.02	2.60	0.77
Net Income / (Loss) Attributable to Noncontrolling Interest	0.02	-0.03	-0.03	-0.03	-0.03	-0.03	-0.03	-0.00	-0.00	-0.04	-0.04
Basic Earnings per Share	($0.20)	($0.22)	($0.22)	($0.31)	($0.33)	($0.48)	($0.35)	($0.33)	($0.40)	($0.27)	($0.32)
Weighted Average Basic Shares Outstanding	149.20M	147.10M	147.52M	147.41M	145.79M	144.38M	144.70M	144.40M	143.51M	142.52M	142.93M
Diluted Earnings per Share	($0.20)	($0.22)	($0.22)	($0.31)	($0.33)	($0.48)	($0.35)	($0.33)	($0.40)	($0.27)	($0.32)
Weighted Average Diluted Shares Outstanding	149.20M	147.10M	147.52M	147.41M	145.79M	144.38M	144.70M	144.40M	143.51M	142.52M	142.93M
Weighted Average Basic & Diluted Shares Outstanding	151.92M	148.58M	147.58M	147.47M	147.37M	145.09M	144.77M	144.65M	144.31M	143.23M	143.01M

This table details how cash moves in and out of Adaptive Biotechnologies' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017
Net Change in Cash & Equivalents	-17	-24	-49	16	27	44	-30	52
Net Cash From Operating Activities	-95	-156	-184	-193	-150	205	-32	-35
Net Cash From Continuing Operating Activities	-95	-156	-184	-193	-150	205	-32	-35
Net Income / (Loss) Continuing Operations	-160	-225	-200	-207	-146	-69	-46	-43
Consolidated Net Income / (Loss)	-160	-225	-200	-207	-146	-69	-46	-43
Depreciation Expense	18	21	19	12	6.77	6.09	4.30	4.10
Amortization Expense	-6.51	-7.49	2.44	8.93	2.48	-2.77	0.49	2.04
Non-Cash Adjustments To Reconcile Net Income	71	102	66	50	28	16	11	7.31
Changes in Operating Assets and Liabilities, net	-17	-46	-72	-57	-41	255	-1.72	-5.48
Net Cash From Investing Activities	78	130	2.91	181	-117	-482	0.74	36
Net Cash From Continuing Investing Activities	78	130	2.91	181	-117	-482	0.74	36
Purchase of Property, Plant & Equipment	-3.66	-11	-16	-62	-19	-11	-6.30	-2.42
Purchase of Investments	-244	-430	-279	-317	-695	-884	-147	-125
Sale and/or Maturity of Investments	326	570	298	560	597	414	154	164
Net Cash From Financing Activities	0.24	2.25	132	27	294	320	1.25	50
Net Cash From Continuing Financing Activities	0.24	2.25	132	27	294	320	1.25	50
Repurchase of Common Equity	0.00	0.00	0.00	0.00	-0.32	-4.99	0.00	0.00
Issuance of Common Equity	0.00	0.00	0.00	0.00	272	321	0.00	0.00
Other Financing Activities, net	0.24	2.25	132	27	22	4.06	1.27	0.22
Cash Interest Paid	8.86	8.99	0.49	0.00	0.00	-	-	-

This table details how cash moves in and out of Adaptive Biotechnologies' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	2.54	9.76	-22	-11	6.20	-24	-21	15	4.50	-128	141
Net Cash From Operating Activities	-28	-12	-27	-17	-38	-27	-47	-24	-59	-30	-42
Net Cash From Continuing Operating Activities	-28	-12	-27	-17	-38	-27	-47	-24	-59	-30	-42
Net Income / (Loss) Continuing Operations	-30	-34	-32	-46	-48	-69	-50	-48	-58	-40	-45
Consolidated Net Income / (Loss)	-30	-34	-32	-46	-48	-69	-50	-48	-58	-40	-45
Depreciation Expense	4.31	4.02	4.16	4.58	4.79	4.96	5.34	5.23	5.00	4.86	4.96
Amortization Expense	-0.54	-1.03	-1.58	-1.68	-2.22	-2.53	-2.27	-1.50	-1.19	-0.66	0.84
Non-Cash Adjustments To Reconcile Net Income	14	15	15	23	17	44	19	20	19	16	16
Changes in Operating Assets and Liabilities, net	-16	3.05	-13	2.83	-10	-3.51	-19	0.45	-24	-10	-19
Net Cash From Investing Activities	26	22	5.29	5.88	45	3.21	26	37	63	-98	58
Net Cash From Continuing Investing Activities	26	22	5.29	5.88	45	3.21	26	37	63	-98	58
Purchase of Property, Plant & Equipment	-1.26	-0.08	-0.34	-1.73	-1.51	-1.30	-2.78	-3.70	-2.92	-2.54	-5.43
Purchase of Investments	-51	-45	-63	-83	-53	-122	-119	-99	-89	-165	-29
Sale and/or Maturity of Investments	77	67	69	90	100	127	148	140	155	70	92
Net Cash From Financing Activities	5.45	0.13	0.04	0.03	0.04	0.09	0.02	1.47	0.67	0.01	126
Net Cash From Continuing Financing Activities	5.45	0.13	0.04	0.03	0.04	0.09	0.02	1.47	0.67	0.01	126
Other Financing Activities, net	5.45	0.13	0.04	0.03	0.04	0.09	0.02	1.47	0.67	125	0.83
Cash Interest Paid	2.37	2.32	2.16	2.09	2.29	1.90	2.45	1.88	2.76	0.49	-

This table presents Adaptive Biotechnologies' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Total Assets	539	661	857	923	1,116	912	333
Total Current Assets	284	410	562	403	727	613	181
Cash & Equivalents	48	65	90	139	123	97	55
Short-Term Investments	174	281	408	214	565	480	110
Accounts Receivable	42	38	40	17	10	13	4.81
Inventories, net	8.44	14	14	19	14	9.07	7.84
Prepaid Expenses	11	11	9.44	13	15	14	3.06
Plant, Property, & Equipment, net	49	68	83	85	40	60	19
Total Noncurrent Assets	207	183	211	435	350	239	133
Long-Term Investments	34	0.00	-	217	119	105	0.00
Goodwill	119	119	119	119	119	119	119
Intangible Assets	3.43	5.13	6.83	8.53	10	12	14
Other Noncurrent Operating Assets	51	59	85	91	102	2.92	0.25
Total Liabilities & Shareholders' Equity	539	661	857	923	1,116	912	333
Total Liabilities	337	353	393	319	373	341	30
Total Current Liabilities	98	88	110	114	105	78	23
Short-Term Debt	0.87	0.00	-	-	-	-	-
Accounts Payable	7.27	7.72	8.08	3.31	3.24	4.45	1.79
Accrued Expenses	8.16	8.60	12	9.34	13	4.37	2.56
Current Deferred Revenue	56	49	64	80	73	61	14
Current Employee Benefit Liabilities	16	14	16	16	12	8.12	4.64
Other Current Liabilities	10	9.38	9.23	5.06	3.53	0.00	-
Total Noncurrent Liabilities	239	265	283	205	268	263	7.14
Long-Term Debt	132	131	125	-	-	-	-
Noncurrent Deferred Revenue	27	45	59	99	164	226	6.81
Other Noncurrent Operating Liabilities	79	89	99	107	104	37	0.34
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	202	308	464	604	743	571	-258
Total Preferred & Common Equity	203	308	464	604	743	571	-258
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	203	308	464	604	743	571	-258
Common Stock	1,506	1,453	1,387	1,324	1,254	936	38
Retained Earnings	-1,304	-1,144	-919	-719	-512	-365	-296
Accumulated Other Comprehensive Income / (Loss)	0.17	0.22	-4.12	-1.14	0.89	0.67	-0.11
Noncontrolling Interest	-0.22	-0.12	-0.07	0.11	0.00	-	-

This table presents Adaptive Biotechnologies' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	3/31/2025	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	511	559	585	620	718	765	791	884
Total Current Assets	256	308	352	374	435	477	501	564
Cash & Equivalents	51	38	60	71	89	109	95	218
Short-Term Investments	143	205	232	238	282	308	346	291
Accounts Receivable	44	41	36	42	31	32	31	27
Inventories, net	8.68	12	13	13	19	19	20	17
Prepaid Expenses	11	12	11	9.85	13	9.07	9.79	12
Plant, Property, & Equipment, net	44	51	55	65	77	79	81	87
Total Noncurrent Assets	210	199	178	178	206	208	209	233
Long-Term Investments	39	24	-	-	-	-	-	20
Goodwill	119	119	119	119	119	119	119	119
Intangible Assets	3.01	3.85	4.28	4.71	5.56	5.99	6.41	7.26
Other Noncurrent Operating Assets	49	52	55	54	81	83	83	87
Total Liabilities & Shareholders' Equity	511	559	585	620	718	765	791	884
Total Liabilities	321	335	343	346	356	369	368	396
Total Current Liabilities	88	88	88	83	93	95	90	104
Short-Term Debt	2.01	-	0.00	0.00	3.19	-	-	-
Accounts Payable	6.36	7.35	9.87	12	4.48	9.16	6.33	4.16
Accrued Expenses	7.76	6.06	6.71	7.91	10	8.36	8.04	11
Current Deferred Revenue	55	52	52	47	55	58	60	68
Current Employee Benefit Liabilities	6.41	12	9.52	6.40	11	11	6.12	13
Other Current Liabilities	10	10	9.81	9.59	9.48	9.35	9.29	8.53
Total Noncurrent Liabilities	233	247	255	263	263	273	277	292
Long-Term Debt	132	133	132	132	127	-	-	-
Noncurrent Deferred Revenue	25	33	39	44	44	51	54	67
Other Noncurrent Operating Liabilities	76	82	84	87	92	222	224	225
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	190	224	241	275	362	396	424	488
Total Preferred & Common Equity	190	224	242	275	362	396	424	488
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	190	224	242	275	362	396	424	488
Common Stock	1,524	1,493	1,480	1,467	1,437	1,422	1,403	1,373
Retained Earnings	-1,334	-1,270	-1,238	-1,192	-1,075	-1,025	-977	-879
Accumulated Other Comprehensive Income / (Loss)	0.13	0.50	-0.18	-0.11	-0.25	-0.89	-1.91	-5.97
Noncontrolling Interest	-0.20	-0.20	-0.17	-0.15	-0.10	-0.07	-0.07	-0.03

This table displays calculated financial ratios and metrics derived from Adaptive Biotechnologies' official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017
Growth Metrics	-	-	-	-	-	-	-	-
Revenue Growth	5.10%	-8.11%	20.06%	56.88%	15.65%	52.83%	254.79%	0.00%
EBITDA Growth	29.20%	-19.86%	4.93%	-30.79%	-91.27%	16.54%	-134.60%	0.00%
EBIT Growth	28.40%	-13.41%	4.20%	-36.74%	2.53%	-57.55%	-123.75%	0.00%
NOPAT Growth	28.40%	-13.41%	4.20%	-36.74%	-94.94%	21.22%	-123.75%	0.00%
Net Income Growth	29.16%	-12.45%	3.34%	-41.76%	-113.14%	-47.71%	-8.44%	0.00%
EPS Growth	30.77%	-11.43%	5.41%	-33.33%	-9.90%	72.48%	-4.86%	0.00%
Operating Cash Flow Growth	39.09%	15.02%	4.56%	-28.76%	-172.87%	736.73%	7.46%	0.00%
Free Cash Flow Firm Growth	36.92%	18.88%	18.96%	-57.52%	-146.62%	196.15%	0.00%	0.00%
Invested Capital Growth	-13.75%	1.40%	169.24%	153.36%	42.90%	-140.39%	0.00%	0.00%
Revenue Q/Q Growth	0.94%	-5.24%	10.28%	-24.10%	107.05%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	19.96%	-18.66%	10.29%	-8.58%	-13.96%	0.00%	0.00%	0.00%
EBIT Q/Q Growth	18.64%	-16.34%	10.07%	-9.06%	-15.10%	0.00%	0.00%	0.00%
NOPAT Q/Q Growth	18.64%	-16.34%	10.07%	-9.06%	-15.10%	0.00%	0.00%	0.00%
Net Income Q/Q Growth	18.30%	-14.95%	9.56%	-34.79%	8.03%	0.00%	0.00%	0.00%
EPS Q/Q Growth	19.40%	-15.56%	10.83%	-8.03%	-211.00%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	13.17%	1.94%	11.46%	-7.82%	-9.55%	-9.43%	0.00%	0.00%
Free Cash Flow Firm Q/Q Growth	6.86%	46.06%	-104.17%	-6.07%	0.00%	0.00%	0.00%	0.00%
Invested Capital Q/Q Growth	-10.41%	-23.16%	328.37%	77.24%	16.96%	0.00%	0.00%	0.00%
Profitability Metrics	-	-	-	-	-	-	-	-
Gross Margin	59.72%	55.63%	68.75%	68.06%	77.10%	73.82%	64.67%	0.06%
EBITDA Margin	-84.66%	-125.67%	-96.34%	-121.66%	-145.93%	-88.24%	-80.79%	-244.36%
Operating Margin	-90.83%	-133.33%	-108.03%	-135.39%	-155.33%	-92.15%	-89.39%	-283.48%
EBIT Margin	-90.83%	-133.33%	-108.03%	-135.39%	-155.33%	-92.15%	-89.39%	-283.48%
Profit (Net Income) Margin	-89.18%	-132.32%	-108.13%	-134.31%	-148.63%	-80.65%	-83.44%	-273.00%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	98.18%	99.24%	100.09%	99.20%	95.69%	87.52%	93.35%	96.30%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-132.04%	-172.93%	-223.93%	0.00%	0.00%	-66.84%	-50.58%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	-104.97%	-150.38%	-211.15%	0.00%	0.00%	-128.25%	-72.99%	0.00%
Return on Net Nonoperating Assets (RNNOA)	69.55%	114.59%	186.41%	0.00%	0.00%	187.16%	19.89%	0.00%
Return on Equity (ROE)	-62.49%	-58.34%	-37.52%	-30.77%	-22.25%	7.46%	-30.68%	0.00%
Cash Return on Invested Capital (CROIC)	-117.27%	-174.32%	-315.60%	-718.96%	0.00%	0.00%	-1,002.31%	0.00%
Operating Return on Assets (OROA)	-27.08%	-29.92%	-22.49%	-20.49%	-15.07%	-12.59%	-29.91%	0.00%
Return on Assets (ROA)	-26.59%	-29.69%	-22.51%	-20.33%	-14.42%	-22.04%	-13.96%	0.00%
Return on Common Equity (ROCE)	-62.54%	-58.35%	-37.51%	-30.77%	-22.25%	8.89%	26.16%	0.00%
Return on Equity Simple (ROE_SIMPLE)	-78.73%	-73.06%	-43.17%	-34.32%	-19.67%	-12.01%	17.99%	0.00%
Net Operating Profit after Tax (NOPAT)	-114	-159	-140	-146	-107	-55	-70	-31
NOPAT Margin	-63.58%	-93.33%	-75.62%	-94.77%	-108.73%	-64.50%	-62.57%	-198.44%
Net Nonoperating Expense Percent (NNEP)	-27.07%	-22.56%	-12.78%	-8.86%	-5.27%	-2.71%	-12.08%	0.00%
Return On Investment Capital (ROIC_SIMPLE)	-33.89%	-36.21%	-23.77%	-	-	-	-	-
Cost of Revenue to Revenue	40.28%	44.37%	31.25%	31.94%	22.90%	26.18%	35.33%	99.94%
SG&A Expenses to Revenue	40.68%	49.29%	47.77%	48.27%	50.35%	35.65%	36.67%	101.66%
R&D to Revenue	57.53%	71.72%	76.50%	92.22%	117.98%	83.11%	70.35%	203.93%
Operating Expenses to Revenue	150.55%	188.96%	176.78%	203.45%	232.43%	165.96%	154.05%	283.54%
Earnings before Interest and Taxes (EBIT)	-163	-227	-200	-209	-153	-157	-100	-44
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-152	-214	-179	-188	-144	-75	-90	-38
Valuation Ratios	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	4.36	2.30	2.35	6.56	10.88	6.51	0.00	0.00
Price to Tangible Book Value (P/TBV)	11.02	3.85	3.23	8.31	13.17	8.45	0.00	0.00
Price to Revenue (P/Rev)	4.94	4.17	5.90	25.66	82.20	43.73	5.39	19.12
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	9.55	5.33	7.89	100.01	0.00	0.00	5.05	0.00
Enterprise Value to Revenue (EV/Rev)	4.26	2.90	3.88	21.96	74.00	35.71	12.50	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	14.79	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	9.15	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-
Debt to Equity	0.66	0.42	0.27	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.65	0.42	0.27	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.66	-0.76	-0.88	-1.02	-1.13	-1.16	-0.55	0.00
Leverage Ratio	2.35	1.97	1.67	1.51	1.54	1.42	1.10	0.00
Compound Leverage Factor	2.31	1.95	1.67	1.50	1.48	1.25	1.03	0.00
Debt to Total Capital	39.69%	29.77%	21.27%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.26%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	39.44%	29.77%	21.27%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	-0.07%	-0.03%	-0.01%	0.02%	0.00%	0.00%	370.51%	0.00%
Common Equity to Total Capital	60.37%	70.26%	78.74%	99.98%	100.00%	200.00%	-85.26%	0.00%
Debt to EBITDA	-0.88	-0.61	-0.70	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.81	1.01	2.09	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	-0.87	-0.61	-0.70	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	-1.17	-0.82	-0.89	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	1.08	1.36	2.66	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	-1.16	-0.82	-0.89	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	-2.06	-1.51	0.25	6.15	12.67	10.08	5.01	0.00
Noncontrolling Interest Sharing Ratio	-0.07%	-0.02%	0.00%	0.01%	0.00%	64.19%	185.26%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-
Current Ratio	2.89	4.66	5.12	3.54	6.91	7.82	15.85	0.00
Quick Ratio	2.69	4.37	4.90	3.26	6.64	7.53	14.90	0.00
Cash Flow Metrics	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-101	-160	-197	-244	-155	332	-345	0.00
Operating Cash Flow to CapEx	-2,598.58%	-1,461.38%	-1,125.11%	-312.13%	-796.06%	1,833.96%	-1,024.26%	-1,574.44%
Free Cash Flow to Firm to Interest Expense	-8.73	-11.61	-46.60	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	-8.22	-11.33	-43.40	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	-8.54	-12.10	-47.26	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-
Asset Turnover	0.30	0.22	0.21	0.15	0.10	0.14	0.17	0.00
Accounts Receivable Turnover	4.49	4.36	6.45	11.24	8.66	9.73	11.58	0.00
Inventory Turnover	6.30	5.23	3.44	2.96	1.95	2.63	2.51	0.00
Fixed Asset Turnover	3.06	2.25	2.20	2.47	1.97	2.14	2.91	0.00
Accounts Payable Turnover	9.62	9.56	10.17	15.07	5.86	7.13	10.97	0.00
Days Sales Outstanding (DSO)	81.28	83.63	56.60	32.46	42.15	37.51	31.52	0.00
Days Inventory Outstanding (DIO)	57.95	69.81	106.26	123.36	187.38	138.53	145.46	0.00
Days Payable Outstanding (DPO)	37.94	38.17	35.90	24.22	62.29	51.18	33.27	0.00
Cash Conversion Cycle (CCC)	101.29	115.27	126.95	131.60	167.24	124.86	143.70	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-
Invested Capital	80	93	91	34	-64	-111	275	0.00
Invested Capital Turnover	2.08	1.85	2.96	-10.42	-1.13	1.04	0.81	0.00
Increase / (Decrease) in Invested Capital	-13	1.28	57	97	48	-387	275	0.00
Enterprise Value (EV)	762	494	720	3,390	7,281	3,038	696	0.00
Market Capitalization	885	709	1,093	3,960	8,087	3,720	300	300
Book Value per Share	$1.37	$2.13	$3.25	$4.28	$5.43	$4.59	($20.44)	$0.00
Tangible Book Value per Share	$0.54	$1.27	$2.37	$3.38	$4.49	$3.54	($61.87)	$0.00
Total Capital	336	439	589	604	743	571	605	0.00
Total Debt	133	131	125	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	132	131	125	0.00	0.00	0.00	0.00	0.00
Net Debt	-123	-216	-373	-570	-807	-682	-330	0.00
Capital Expenditures (CapEx)	3.66	11	16	62	19	11	13	2.21
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-36	-24	-46	-64	-67	-42	-14	0.00
Debt-free Net Working Capital (DFNWC)	187	322	452	289	622	534	158	0.00
Net Working Capital (NWC)	186	322	452	289	622	534	316	0.00
Net Nonoperating Expense (NNE)	46	66	60	61	39	14	23	12
Net Nonoperating Obligations (NNO)	-123	-216	-373	-570	-807	-682	-330	0.00
Total Depreciation and Amortization (D&A)	11	13	22	21	9.25	3.33	9.57	6.14
Debt-free, Cash-free Net Working Capital to Revenue	-19.97%	-14.23%	-24.74%	-41.54%	-67.65%	-49.95%	-25.51%	0.00%
Debt-free Net Working Capital to Revenue	104.25%	189.21%	244.11%	187.21%	631.94%	628.15%	283.70%	0.00%
Net Working Capital to Revenue	103.77%	189.21%	244.11%	187.21%	631.94%	1,914.20%	283.70%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($1.08)	($1.56)	($1.40)	($1.48)	($1.11)	($1.01)	($3.67)	($3.50)
Adjusted Weighted Average Basic Shares Outstanding	147.10M	144.38M	142.52M	141.58M	139.22M	126.32M	12.63M	12.20M
Adjusted Diluted Earnings per Share	($1.08)	($1.56)	($1.40)	($1.48)	($1.11)	($1.01)	($3.67)	($3.50)
Adjusted Weighted Average Diluted Shares Outstanding	147.10M	144.38M	142.52M	141.58M	139.22M	126.32M	12.63M	12.20M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	($1.48)	($1.11)	($1.01)	($3.67)	($3.50)
Adjusted Weighted Average Basic & Diluted Shares Outstanding	148.58M	145.09M	143.23M	140.35M	131.22M	69.17M	12.63M	12.20M
Normalized Net Operating Profit after Tax (NOPAT)	-109	-141	-140	-146	-107	-55	-70	-31
Normalized NOPAT Margin	-60.76%	-82.88%	-75.62%	-94.77%	-108.73%	-64.50%	-62.57%	-194.69%
Pre Tax Income Margin	-89.18%	-132.32%	-108.13%	-134.31%	-148.63%	-80.65%	-83.44%	-273.00%
Debt Service Ratios	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-14.04	-16.45	-47.24	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	-9.83	-11.52	-33.07	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	-14.35	-17.23	-51.09	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	-10.14	-12.29	-36.92	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	-0.22%	-14.54%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Adaptive Biotechnologies' official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	25.24%	3.66%	22.46%	-11.72%	11.23%	-17.06%	-20.72%	12.06%	-2.52%	45.53%	21.19%
EBITDA Growth	44.08%	55.06%	37.26%	-0.75%	13.47%	-96.19%	-20.82%	5.71%	6.60%	36.93%	22.30%
EBIT Growth	39.29%	52.39%	35.96%	1.05%	14.74%	-81.36%	-12.16%	8.92%	9.31%	36.38%	19.34%
NOPAT Growth	39.29%	52.39%	35.96%	1.05%	14.74%	-81.36%	-12.16%	8.92%	9.31%	36.38%	19.34%
Net Income Growth	37.24%	51.46%	36.22%	3.27%	17.62%	-72.94%	-11.05%	8.20%	8.12%	34.53%	19.07%
EPS Growth	39.39%	54.17%	37.14%	6.06%	17.50%	-77.78%	-9.38%	10.81%	9.09%	38.64%	20.00%
Operating Cash Flow Growth	25.73%	53.62%	42.03%	26.55%	35.16%	10.28%	-10.08%	49.95%	8.22%	44.23%	2.38%
Free Cash Flow Firm Growth	87.80%	78.52%	104.34%	-345.34%	-594.78%	39.83%	-818.56%	155.09%	125.26%	39.66%	120.20%
Invested Capital Growth	-3.24%	-13.75%	-26.03%	483.92%	661.72%	1.40%	401.35%	-131.43%	-131.84%	169.24%	-308.97%
Revenue Q/Q Growth	10.50%	2.21%	7.51%	3.15%	-8.54%	20.74%	-22.50%	29.96%	-31.80%	15.40%	9.55%
EBITDA Q/Q Growth	16.26%	-2.66%	32.34%	3.85%	32.70%	-43.32%	-8.64%	17.42%	-52.58%	11.74%	15.22%
EBIT Q/Q Growth	12.51%	-3.69%	31.04%	2.96%	31.39%	-39.47%	-6.56%	16.39%	-45.95%	13.75%	13.47%
NOPAT Q/Q Growth	12.51%	-3.69%	31.04%	2.96%	31.39%	-39.47%	-6.56%	16.39%	-45.95%	13.75%	13.47%
Net Income Q/Q Growth	11.53%	-5.05%	30.60%	2.70%	31.57%	-38.03%	-5.26%	17.14%	-43.64%	11.36%	12.99%
EPS Q/Q Growth	9.09%	0.00%	29.03%	6.06%	31.25%	-37.14%	-6.06%	17.50%	-48.15%	15.63%	13.51%
Operating Cash Flow Q/Q Growth	-128.04%	53.85%	-56.42%	54.88%	-42.41%	42.31%	-98.18%	60.18%	-97.05%	29.21%	9.89%
Free Cash Flow Firm Q/Q Growth	-61.30%	-228.83%	106.25%	6.15%	-184.04%	73.98%	-453.64%	89.28%	134.54%	-410.78%	127.11%
Invested Capital Q/Q Growth	14.02%	-10.41%	9.12%	-13.20%	1.63%	-23.16%	666.37%	-27.00%	-118.35%	328.37%	-159.07%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	67.62%	61.98%	64.11%	55.27%	56.89%	57.16%	48.98%	63.39%	50.38%	69.95%	68.83%
EBITDA Margin	-49.26%	-65.00%	-64.71%	-102.83%	-110.31%	-149.91%	-126.30%	-90.10%	-141.79%	-63.38%	-82.87%
Operating Margin	-56.45%	-71.30%	-70.27%	-109.56%	-116.45%	-155.22%	-134.38%	-97.74%	-151.92%	-70.99%	-94.98%
EBIT Margin	-56.45%	-71.30%	-70.27%	-109.56%	-116.45%	-155.22%	-134.38%	-97.74%	-151.92%	-70.99%	-94.98%
Profit (Net Income) Margin	-56.88%	-71.04%	-69.12%	-107.08%	-113.52%	-151.73%	-132.72%	-97.72%	-153.27%	-72.77%	-94.75%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	100.76%	99.65%	98.36%	97.74%	97.48%	97.75%	98.76%	99.99%	100.89%	102.51%	99.75%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-80.94%	-103.64%	-83.25%	-428.79%	-368.01%	-201.33%	-420.13%	-559.27%	-1,093.91%	-147.15%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	-74.43%	-97.72%	-78.33%	-424.24%	-363.70%	-194.62%	-416.32%	-555.97%	-1,090.15%	-144.45%	0.00%
Return on Net Nonoperating Assets (RNNOA)	44.81%	64.74%	50.28%	384.06%	323.46%	148.31%	376.88%	527.76%	1,050.17%	127.53%	0.00%
Return on Equity (ROE)	-36.13%	-38.90%	-32.97%	-44.73%	-44.55%	-53.01%	-43.25%	-31.51%	-43.74%	-19.63%	-38.89%
Cash Return on Invested Capital (CROIC)	-105.19%	-117.27%	-103.57%	-313.07%	-280.51%	-174.32%	-246.62%	0.00%	0.00%	-315.60%	0.00%
Operating Return on Assets (OROA)	-18.92%	-21.26%	-19.52%	-27.40%	-28.79%	-34.83%	-30.15%	-23.59%	-33.95%	-14.78%	-17.01%
Return on Assets (ROA)	-19.06%	-21.18%	-19.20%	-26.78%	-28.06%	-34.04%	-29.78%	-23.58%	-34.25%	-15.15%	-16.97%
Return on Common Equity (ROCE)	-36.16%	-38.93%	-32.98%	-44.75%	-44.57%	-53.03%	-43.25%	-31.51%	-43.74%	-19.63%	-38.89%
Return on Equity Simple (ROE_SIMPLE)	-74.51%	0.00%	-87.30%	-88.40%	-78.26%	0.00%	-54.19%	-48.23%	-46.05%	0.00%	-45.42%
Net Operating Profit after Tax (NOPAT)	-21	-24	-23	-33	-34	-50	-36	-33	-40	-27	-32
NOPAT Margin	-39.51%	-49.91%	-49.19%	-76.69%	-81.52%	-108.66%	-94.07%	-68.41%	-106.34%	-49.69%	-66.49%
Net Nonoperating Expense Percent (NNEP)	-6.51%	-5.93%	-4.93%	-4.55%	-4.31%	-6.70%	-3.81%	-3.30%	-3.75%	-2.70%	-2.33%
Return On Investment Capital (ROIC_SIMPLE)	-6.40%	-7.05%	-	-	-	-11.33%	-	-	-	-4.65%	-
Cost of Revenue to Revenue	32.38%	38.02%	35.89%	44.73%	43.11%	42.84%	51.02%	36.61%	49.62%	30.05%	31.17%
SG&A Expenses to Revenue	33.18%	38.05%	37.17%	41.43%	46.80%	45.27%	52.94%	45.58%	55.33%	40.63%	43.39%
R&D to Revenue	46.15%	48.87%	52.04%	58.70%	72.23%	62.79%	75.25%	65.89%	86.60%	56.56%	74.55%
Operating Expenses to Revenue	124.07%	133.28%	134.38%	164.83%	173.34%	212.38%	183.36%	161.13%	202.30%	140.94%	163.82%
Earnings before Interest and Taxes (EBIT)	-30	-34	-33	-47	-49	-71	-51	-48	-57	-39	-45
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-26	-31	-30	-44	-46	-69	-48	-44	-53	-35	-40
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	5.80	4.36	3.37	2.21	1.69	2.30	2.18	2.45	2.98	2.35	2.09
Price to Tangible Book Value (P/TBV)	16.13	11.02	7.48	4.51	3.08	3.85	3.32	3.57	4.23	3.23	2.81
Price to Revenue (P/Rev)	5.82	4.94	4.26	3.16	2.67	4.17	4.39	5.11	6.86	5.90	6.05
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	11.04	9.55	6.96	4.58	3.07	5.33	4.54	0.00	0.00	7.89	0.00
Enterprise Value to Revenue (EV/Rev)	5.30	4.26	3.50	2.21	1.65	2.90	3.04	2.91	4.47	3.88	2.91
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.70	0.66	0.59	0.55	0.48	0.42	0.36	0.00	0.00	0.27	0.00
Long-Term Debt to Equity	0.69	0.65	0.59	0.55	0.48	0.42	0.35	0.00	0.00	0.27	0.00
Financial Leverage	-0.60	-0.66	-0.64	-0.91	-0.89	-0.76	-0.91	-0.95	-0.96	-0.88	-1.02
Leverage Ratio	2.43	2.35	2.18	2.12	2.02	1.97	1.89	1.72	1.69	1.67	1.65
Compound Leverage Factor	2.45	2.34	2.15	2.07	1.97	1.92	1.86	1.72	1.70	1.71	1.64
Debt to Total Capital	41.25%	39.69%	37.25%	35.36%	32.38%	29.77%	26.43%	0.00%	0.00%	21.27%	0.00%
Short-Term Debt to Total Capital	0.62%	0.26%	0.00%	0.00%	0.00%	0.00%	0.65%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	40.63%	39.44%	37.25%	35.36%	32.38%	29.77%	25.78%	0.00%	0.00%	21.27%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	-0.06%	-0.07%	-0.06%	-0.05%	-0.04%	-0.03%	-0.02%	-0.02%	-0.02%	-0.01%	-0.01%
Common Equity to Total Capital	58.81%	60.37%	62.81%	64.68%	67.66%	70.26%	73.59%	100.02%	100.02%	78.74%	100.01%
Debt to EBITDA	-1.02	-0.88	-0.70	-0.64	-0.64	-0.61	-0.72	0.00	0.00	-0.70	0.00
Net Debt to EBITDA	0.76	0.81	0.71	0.77	0.86	1.01	1.34	0.00	0.00	2.09	0.00
Long-Term Debt to EBITDA	-1.00	-0.87	-0.70	-0.64	-0.64	-0.61	-0.70	0.00	0.00	-0.70	0.00
Debt to NOPAT	-1.33	-1.17	-0.95	-0.87	-0.86	-0.82	-0.95	0.00	0.00	-0.89	0.00
Net Debt to NOPAT	0.99	1.08	0.96	1.05	1.16	1.36	1.77	0.00	0.00	2.66	0.00
Long-Term Debt to NOPAT	-1.31	-1.16	-0.95	-0.87	-0.86	-0.82	-0.93	0.00	0.00	-0.89	0.00
Altman Z-Score	-1.01	-1.27	-1.23	-1.47	-1.30	-0.73	-0.18	0.34	0.95	0.87	0.79
Noncontrolling Interest Sharing Ratio	-0.08%	-0.07%	-0.05%	-0.04%	-0.03%	-0.02%	-0.01%	-0.01%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.92	2.89	3.52	3.99	4.51	4.66	4.67	5.00	5.56	5.12	5.43
Quick Ratio	2.70	2.69	3.24	3.72	4.23	4.37	4.31	4.71	5.23	4.90	5.14
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-18	-11	8.51	-136	-145	-51	-196	55	29	-85	27
Operating Cash Flow to CapEx	-2,262.43%	-15,613.75%	-7,867.73%	-1,000.75%	-2,538.25%	-2,074.88%	-1,680.49%	-637.17%	-2,022.98%	-1,180.92%	-780.71%
Free Cash Flow to Firm to Interest Expense	-6.09	-3.71	2.89	-50.45	-48.42	-16.94	-53.69	15.38	8.30	-23.65	41.78
Operating Cash Flow to Interest Expense	-9.81	-4.23	-9.21	-6.42	-12.81	-8.94	-12.78	-6.53	-16.75	-8.37	-64.94
Operating Cash Flow Less CapEx to Interest Expense	-10.24	-4.26	-9.33	-7.06	-13.32	-9.37	-13.54	-7.56	-17.58	-9.08	-73.26
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.34	0.30	0.28	0.25	0.25	0.22	0.22	0.24	0.22	0.21	0.18
Accounts Receivable Turnover	4.43	4.49	4.92	5.03	4.78	4.36	6.22	6.86	6.89	6.45	7.70
Inventory Turnover	6.46	6.30	4.68	4.74	4.52	5.23	3.94	3.61	3.10	3.44	3.13
Fixed Asset Turnover	3.46	3.06	2.77	2.50	2.38	2.25	2.20	2.28	2.20	2.20	1.93
Accounts Payable Turnover	7.66	9.62	12.45	8.02	8.10	9.56	16.78	11.46	10.32	10.17	8.97
Days Sales Outstanding (DSO)	82.43	81.28	74.14	72.62	76.34	83.63	58.66	53.19	52.96	56.60	47.43
Days Inventory Outstanding (DIO)	56.48	57.95	77.92	76.93	80.78	69.81	92.69	101.15	117.67	106.26	116.61
Days Payable Outstanding (DPO)	47.63	37.94	29.32	45.50	45.07	38.17	21.76	31.85	35.38	35.90	40.70
Cash Conversion Cycle (CCC)	91.28	101.29	122.74	104.05	112.05	115.27	129.60	122.49	135.24	126.95	123.35
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	91	80	89	82	94	93	120	-21	-17	91	-40
Invested Capital Turnover	2.05	2.08	1.69	5.59	4.51	1.85	4.47	8.17	10.29	2.96	-16.13
Increase / (Decrease) in Invested Capital	-3.05	-13	-31	103	111	1.28	160	-89	-69	57	-59
Enterprise Value (EV)	1,005	762	620	374	288	494	547	551	824	720	489
Market Capitalization	1,104	885	755	533	466	709	788	968	1,265	1,093	1,017
Book Value per Share	$1.28	$1.37	$1.52	$1.64	$1.89	$2.13	$2.50	$2.74	$2.96	$3.25	$3.41
Tangible Book Value per Share	$0.46	$0.54	$0.68	$0.80	$1.04	$1.27	$1.64	$1.88	$2.09	$2.37	$2.53
Total Capital	324	336	356	374	406	439	492	396	424	589	488
Total Debt	134	133	133	132	132	131	130	0.00	0.00	125	0.00
Total Long-Term Debt	132	132	133	132	132	131	127	0.00	0.00	125	0.00
Net Debt	-99	-123	-134	-160	-177	-216	-241	-417	-441	-373	-528
Capital Expenditures (CapEx)	1.26	0.08	0.34	1.73	1.51	1.30	2.78	3.70	2.92	2.54	5.43
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-23	-36	-23	-28	-18	-24	-26	-36	-29	-46	-48
Debt-free Net Working Capital (DFNWC)	171	187	221	263	291	322	345	381	411	452	460
Net Working Capital (NWC)	169	186	221	263	291	322	342	381	411	452	460
Net Nonoperating Expense (NNE)	9.11	10	9.25	13	13	20	15	14	18	13	14
Net Nonoperating Obligations (NNO)	-99	-123	-134	-160	-181	-216	-241	-417	-441	-373	-528
Total Depreciation and Amortization (D&A)	3.77	2.99	2.58	2.90	2.57	2.43	3.07	3.74	3.81	4.20	5.79
Debt-free, Cash-free Net Working Capital to Revenue	-11.99%	-19.97%	-12.75%	-16.86%	-10.19%	-14.23%	-14.47%	-18.86%	-15.98%	-24.74%	-28.40%
Debt-free Net Working Capital to Revenue	90.06%	104.25%	124.50%	156.09%	166.81%	189.21%	192.07%	201.20%	223.09%	244.11%	273.96%
Net Working Capital to Revenue	89.00%	103.77%	124.50%	156.09%	166.81%	189.21%	190.29%	201.20%	223.09%	244.11%	273.96%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.20)	($0.22)	($0.22)	($0.31)	($0.33)	($0.48)	($0.35)	($0.33)	($0.40)	($0.27)	($0.32)
Adjusted Weighted Average Basic Shares Outstanding	149.20M	147.10M	147.52M	147.41M	145.79M	144.38M	144.70M	144.40M	143.51M	142.52M	142.93M
Adjusted Diluted Earnings per Share	($0.20)	($0.22)	($0.22)	($0.31)	($0.33)	($0.48)	($0.35)	($0.33)	($0.40)	($0.27)	($0.32)
Adjusted Weighted Average Diluted Shares Outstanding	149.20M	147.10M	147.52M	147.41M	145.79M	144.38M	144.70M	144.40M	143.51M	142.52M	142.93M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	151.92M	148.58M	147.58M	147.47M	147.37M	145.09M	144.77M	144.65M	144.31M	143.23M	143.01M
Normalized Net Operating Profit after Tax (NOPAT)	-21	-24	-23	-28	-34	-32	-36	-33	-40	-27	-32
Normalized NOPAT Margin	-39.51%	-49.91%	-49.19%	-65.01%	-81.52%	-69.78%	-94.07%	-68.41%	-106.34%	-49.69%	-66.49%
Pre Tax Income Margin	-56.88%	-71.04%	-69.12%	-107.08%	-113.52%	-151.73%	-132.72%	-97.72%	-153.27%	-72.77%	-94.75%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-10.19	-11.46	-11.10	-17.55	-16.29	-23.60	-13.95	-13.26	-16.20	-10.93	-69.57
NOPAT to Interest Expense	-7.13	-8.02	-7.77	-12.29	-11.40	-16.52	-9.77	-9.29	-11.34	-7.65	-48.70
EBIT Less CapEx to Interest Expense	-10.62	-11.49	-11.22	-18.19	-16.80	-24.03	-14.71	-14.29	-17.03	-11.64	-77.89
NOPAT Less CapEx to Interest Expense	-7.57	-8.05	-7.89	-12.93	-11.91	-16.95	-10.53	-10.31	-12.17	-8.36	-57.02
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Adaptive Biotechnologies' Financials

When does Adaptive Biotechnologies's financial year end?

According to the most recent income statement we have on file, Adaptive Biotechnologies' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Adaptive Biotechnologies' net income changed over the last 7 years?

Adaptive Biotechnologies' net income appears to be on an upward trend, with a most recent value of -$159.60 million in 2024, rising from -$42.83 million in 2017. The previous period was -$225.30 million in 2023. Check out Adaptive Biotechnologies' forecast to explore projected trends and price targets.

What is Adaptive Biotechnologies's operating income?

Adaptive Biotechnologies's total operating income in 2024 was -$162.55 million, based on the following breakdown:

Total Gross Profit: $106.88 million
Total Operating Expenses: $269.43 million

How has Adaptive Biotechnologies revenue changed over the last 7 years?

Over the last 7 years, Adaptive Biotechnologies' total revenue changed from $15.69 million in 2017 to $178.96 million in 2024, a change of 1,040.7%.

How much debt does Adaptive Biotechnologies have?

Adaptive Biotechnologies' total liabilities were at $336.89 million at the end of 2024, a 4.5% decrease from 2023, and a 1,025.1% increase since 2018.

How much cash does Adaptive Biotechnologies have?

In the past 6 years, Adaptive Biotechnologies' cash and equivalents has ranged from $47.92 million in 2024 to $139.07 million in 2021, and is currently $47.92 million as of their latest financial filing in 2024.

How has Adaptive Biotechnologies' book value per share changed over the last 7 years?

Over the last 7 years, Adaptive Biotechnologies' book value per share changed from 0.00 in 2017 to 1.37 in 2024, a change of 137.4%.

Related Companies

This page (NASDAQ:ADPT) was last updated on 5/28/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Adaptive Biotechnologies (ADPT) Financials

Frequently Asked Questions About Adaptive Biotechnologies' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Adaptive Biotechnologies (ADPT) Financials

Annual Income Statements for Adaptive Biotechnologies

Quarterly Income Statements for Adaptive Biotechnologies

Annual Cash Flow Statements for Adaptive Biotechnologies

Quarterly Cash Flow Statements for Adaptive Biotechnologies

Annual Balance Sheets for Adaptive Biotechnologies

Quarterly Balance Sheets for Adaptive Biotechnologies

Annual Metrics And Ratios for Adaptive Biotechnologies

Quarterly Metrics And Ratios for Adaptive Biotechnologies

Frequently Asked Questions About Adaptive Biotechnologies' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools